Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
–4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with zorevunersen on top of standard of care anti-seizure medicines–
Covered in this story
What has happened since
- Biogen is up 8.3% since this was published, 46 days ago.
- Stoke Therapeutics Inc is down 9.7% since this was published, 46 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Biogen
- BMO Capital Markets: $229 → $220 by Oct 2027 · Market Perform via Investing.com
- Wolfe Research: $216 → $300 by Sep 2027 · Outperform via Yahoo Finance
- H.C. Wainwright: $203 → $251 by Jul 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $BIIB yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Biogen →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.